While the market grapples with the full impact of the Wuhan coronavirus, long-term investors typically follow Beijing’s policy playbook when deploying their capital. And if they don't, they probably should.
As governments across Asia explore the upside of legalising medicinal marijuana and China expands its already substantial hemp production capabilities, major players in the fast-growing international cannabis economy see the region as a key emerging market.
The drug developer will be the second biotech firm to list in Hong Kong without any profits or revenues. It believes that China’s underpenetrated biologics market provides a massive opportunity in the long run.